Semisynthetic, recombinant, non-oncogenic HPV-16 E7 lipoprotein vaccine against cervical cancer
What is it about?
We developed a non-oncogenic recombinant human papillomavirus type-16 (HPV-16) E7 protein, incorporating the PADRE1024.03 universal T helper epitope, and site-specifically conjugated a chemically synthesised Pam2Cys to the proteins C-terminus. This defined protein was assessed for its capacity to clear a cervical cancer model in mice.
Why is it important?
Cervical cancer is an important cancer in females, with ~ 50% of cervical cancers associated with HPV-16 infection. We have created a defined subunit vaccine, with a built in adjuvant, that could serve as a platform for the further development of commercial vaccines against HPV-16 associated cervical cancers.
The following have contributed to this page: Dr Peter Michael Moyle and Miss Wei WD Dai